Quick Answer
Aquestive Therapeutics, Inc. reported Operating Income Loss of -$71.05 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -130.9% in Operating Income Loss from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Aquestive Therapeutics, Inc.'s Operating Income Loss has declined by 62,777.0%.
- Historical annual values: Fiscal year 2025: -$71.05 million | Fiscal year 2024: -$30.77 million | Fiscal year 2023: -$15.10 million | Fiscal year 2022: -$42.07 million | Fiscal year 2021: -$34.68 million | Fiscal year 2020: -$42.89 million | Fiscal year 2019: -$52.67 million | Fiscal year 2018: -$48.93 million | Fiscal year 2017: -$113.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: